Dear LabPulse reader,
This week, advances in diagnostic technology for cancer were featured in some of our most-read stories. First, Roche announced it received 510(k) clearance from the U.S. Food and Drug Administration for its Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail, an assay designed to help pathologists differentiate a B-cell malignancy from a reactive response to an infection. In developing diagnostics, researchers at Oxford University published findings on a promising liquid biopsy test that uses machine learning to detect six forms of cancer in their earliest stages.
On the topic of liquid biopsies, Mayo Clinic Laboratories and oncology diagnostics firm Lucence announced a strategic collaboration in which Lucence's LiquidHallmark liquid biopsy test will be provided through Mayo Clinic Laboratories.
Oncology wasn't the only area in which diagnostic advances captured readers' attention; diagnostics in neurological disorders also made news. Spanish firm Grifols has received $21 million from the Michael J. Fox Foundation to fund a pilot study analyzing the company's repository of longitudinal Parkinson's disease plasma samples. Grifols, which operates 390 plasma collection centers globally, seeks to develop an early-warning system for the emergence of Parkinson's disease.
Meanwhile, Beckman Coulter Diagnostics announced the release of new research use only blood-based biomarker immunoassays designed for neurodegenerative disease research.
Thanks for reading.
